Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: Relationship with erythropoietin requirements

American Journal of Kidney Diseases

Volumn 38, Issue 3, 2001, Pages 510-517

  Le Meur, Yannick ^a,b   Lorgeot, Valerie ^a,b   Comte, Lydie ^a,b   Szelag, Jean Christophe ^a,b   Aldigier, Jean Claude ^a,b   Leroux Robert, Claude ^a,b   Praloran, Vincent ^a,b  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

Author keywords

Anemia; Angiotensin converting enzyme (ACE) inhibitors; Chronic renal failure (CRF); Erythropoietin (EPO); Hemodialysis (HD); N acetyl seryl aspartyl lysyl proline (AcSDKP)

Indexed keywords

BENAZEPRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; RECOMBINANT ERYTHROPOIETIN; SERASPENIDE; TRANDOLAPRIL;

ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG RESPONSE; ERYTHROPOIESIS; HALF LIFE TIME; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; PARAMETER; UREMIA;

EID: 0034861950     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.26839     Document Type: Article

References (39)

1. The physiological role of the endogenous CFU-S inhibitor acetyl-N-Ser-Asp-Lys-Pro (Ac-SDKP)
2. Inhibitory peptides in hematopoiesis
3. Inhibition of CFU entry into cycle by a bone marrow extract
4. Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP
5. + subpopulation in response to growth factors
6. The tetrapeptide AcSDKP, a negative regulator of cell cycle entry, inhibits the proliferation of human and chicken lymphocytes
7. Negative regulator of pluripotent hemopoietic stem cell proliferation in human white blood cells and plasma as analyzed by enzyme immunoassay
8. Production and consumption of the tetrapeptide AcSDKP, a negative regulator of hematopoietic stem cells, by hematopoietic microenvironmental cells
9. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme
10. A new physiological role of ACE in the regulation of hematopoiesis
11. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline
12. Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progeniors and acetyl-N-Ser-Asp-Lys-Pro concentrations
13. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: A new marker of chronic angiotensin-converting enzyme inhibition
14. Is AcSDKP level a reliable marker of chronic angiotensin I-converting enyme inhibition in hypertensive patients?
15. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin
16. Peripheral blood mononuclear cells from patients with chronic renal failure release factors which suppress erythropoietin secretion in vitro
17. Do polyamines play a role in the pathogenesis of the anemia of end-stage renal disease?
18. Hemodialysis and continuous peritoneal dialysis effects on erythropoiesis in renal failure
19. Effects of parathyroid hormone on erythropoiesis
20. The beneficial effect of enalapril on erythrocytosis after renal transplantation
21. Enalapril (MK-421) and the white cell count and haematocrit
22. Enalapril-associated anemia in renal transplant recipints treated for hypertension
23. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin
24. Involvement of human plasma angiotensin I-converting enyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline
25. Is erythropoietin a survival factor for red blood cells?
26. Erythropoietin in chronic renal failre
27. Effect of serum parathyoid hormone and bone marrow fibrosis on the response to erythropoietin in uremia
28. High Ceactive protein is a strong predictor of resistance to erythrooietin in hemodialysis patients
29. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease
30. Does captopril decrease the effect of human recombinant erythropoietin in haemodialysis patients?
31. Worsening of anemia induced by long-term use of captopril in hemodialysis patients
32. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients
33. High dose enalapril impairs the response to erythropoietin treatment in hemodialysis patients
34. Effect of losartan on haemoglobin concentration in renal transplant recipients - A retrospective analysis
35. Interrelation of the renin system and erythropoietin in rats
36. Effect of angiotensin infusion on extrarenal erythropoietin production
37. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients
38. Angiotensin II stimulates proliferation of normal early erythroid progenitors
39. Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease